Aurobindo Pharma receives 'warning letter' from SEBI over USFDA audit row - Moneycontrol

Aurobindo Pharma "disclosed very limited and restricted information" about the warning it had received from the American drug regulator, SEBI said.

Drug-maker Aurobindo Pharma on June 27 informed the stock exchanges that it has received a "warning letter" from the Securities and Exchange Board of India (SEBI) over the row involving the audit by … [+3103 chars]

full article...